Metastatic breast cancer affects people in many ways. The symptoms experienced by each person will vary based on the parts of ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Several studies show that isolation is very common among those diagnosed with metastatic breast cancer. However, there are ...

BriaCell Therapeutics (TSX:BCT) is reporting that the first metastatic breast cancer patient treated with its Bria-OTS ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

The author reflects on living with HER2-positive metastatic breast cancer for over a decade, highlighting significant milestones and challenges. The eleventh year is viewed as a new beginning, ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period last year.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...